Gospel of lung cancer! New research can successfully target 85% of lung cancer!
A new study shows that combining the two currently available and approved drugs with new treatments can successfully target the current 85% of lung cancer. Compared with traditional chemotherapy, there are fewer side effects; the new treatment plan will enter the second phase of human clinical trials within 12 months. Much work has been done recently to reveal the role of epidermal growth factor receptor (EGFR) in lung cancer. New drugs that inhibit EGFR have been developed and approved for the treatment of non-small cell lung cancer (NSCLCs), but they show very limited efficacy, usually only 10% to 15%. Amyn Habib, the first author of the new study, explained: "In the past few years, great efforts have been made to block EGFR as a treatment for lung cancer, but the therapy is only suitable for a small number of patients. Lung cancer will still pass through each Ways to resist." The study of tracking and blocking the above “various pathways†has become the basis for new research by Haib and his research team. The researchers found that when EGFR is blocked, another protein called tumor necrosis factor (TNF) rises. Therefore, when used in combination with TNF inhibitors, it seems reasonable to explore whether EGFR inhibitors will treat lung cancer more effectively. In animal studies, the researchers found that non-small cell lung cancer is more sensitive to EGFR inhibitors when TNF is blocked. In these early experiments, the researchers used a drug called thalidomide as the main TNF inhibitor. Although the history of thalidomide includes a lot of controversy, it has recently been evaluated as a useful anticancer agent. Since these two drugs have been approved by the FDA for human use, it is hoped that the second phase of human clinical trials of the new dual drug therapy will be accelerated. The proposed clinical trials include not only lung cancer patients, but also those with glioblastoma (this is another cancer known to be associated with EGFR). Oncologist David Gerber, who is about to lead the clinical trial, said: "If this strategy proves to be effective, it will not only be widely used in the treatment of lung cancer, but also widely used in other cancers that express EGFR, including the brain. Cancer, colon cancer, head and neck cancer, etc." Non-small cell lung cancer accounts for almost 85% of all lung cancers, so this new finding is very important in the field of cancer research. If the effectiveness of this therapy is demonstrated in human experiments, it will fundamentally change the treatment of lung cancer. Feature: Industrial Gloves,Construction Gloves,Construction Work Gloves,Industrial Nitrile Gloves Jiangsu Asbao Medical Technology Co., Ltd. , https://www.iigloves.com
1. Made of high‑quality nitrile rubber material, which has excellent wear resistance and long service life.
2. The non‑slip texture on the surface provides ideal grip in dry and oily environments.
3. The interior of the gloves is made of cotton flocking, which provides users with a comfortable hand touch.
4. It can be widely used in agriculture and gardening, metal processing, pesticide industry, petroleum and gasoline refineries, etc.
5. The anti-permeability level of chemicals such as n-heptane, sodium hydroxide and concentrated sulfuric acid reaches level 2 or above (30 minutes), suitable for immersion operation.
Specification:
Item Type: Gloves
Material: Nitrile Rubber + Cotton Flocking
Uses: Agriculture and gardening/metal processing/peroxide/pesticide industry/petroleum and gasoline refineries/automotive and supply industries
Function: Protection from saturated hydrocarbons/inorganic bases/organic bases/inorganic acids
